LAUSR

Extracorporeal membrane oxygenation (ECMO) is a selectively available therapeutic option, generally available in a large‐size referral healthcare system. In a single‐center experience of the use of venovenous ECMO for COVID‐19 ARDS in a medium‐size healthcare system during the pandemic, West et al. in their study have convincingly demonstrated that ECMO can become a broadly available therapeutic option without compromising quality.